

| |
|--------------------------------------|
| PATENT ASSIGNMENT COVER SHEET |
|--------------------------------------|

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4491914

| | |
|---|----------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| TAUSEEF AHMED | 01/29/2015 |
| RECEIVING PARTY DATA | |
| Name: | TAPESTRY PHARMACEUTICALS, INC. |
| Street Address: | 80 SEVILLE CHASE |
| City: | ATLANTA |
| State/Country: | GEORGIA |
| Postal Code: | 30328 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 15483551 |
| CORRESPONDENCE DATA | |
| Fax Number: | (215)963-5001 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 215-963-4764 |
| Email: | barbara.mcgregor@morganlewis.com |
| Correspondent Name: | SHARON B. MCCULLEN |
| Address Line 1: | 1701 MARKET STREET |
| Address Line 2: | 8TH FLOOR |
| Address Line 4: | PHILADELPHIA, PENNSYLVANIA 19103 |
| ATTORNEY DOCKET NUMBER: | 100244-5003-US04 |
| NAME OF SUBMITTER: | SHARON B. MCCULLEN |
| SIGNATURE: | /sharon b mccullen/ |
| DATE SIGNED: | 07/06/2017 |
| Total Attachments: 6 | |
| source=Ahmed#page1.tif | |
| source=Ahmed#page2.tif | |
| source=Ahmed#page3.tif | |
| source=Ahmed#page4.tif | |
| source=Ahmed#page5.tif | |

ASSIGNMENT

WHEREAS, WE, James D. McChesney, a citizen of the United States of America, with a post office address of 147 Country Road 245, Etta, Mississippi (MS) 00820; and **Gilles Tapolsky**, a citizen of the United States of America, with a post office address of 5117 Long Knife Run, Louisville, Kentucky (KY) 40207; and **David L. Emerson**, a citizen of the United States of America, with a post office address of 2440 Mallard Drive, Longmont, Colorado (CO) 80504; and **John Marshall**, a citizen of the United States of America, with a post office address of 3800 Reservoir Road, NW, Washington, District of Columbia (DC) 20007; and **Tauseef Ahmed**, a citizen of the United States of America, with a post office address of 49 Brookwood Dr, Briarcliff Manor, New York (NY) 10510; and **Allen Cohn**, a citizen of the United States of America, with a post office address of 10460 E. Aberdeen Ave, Englewood, Colorado (CO) 80111-5478; and **Michael Kurman**, a citizen of the United States of America, with a post office address of 469 W. Saddle River Road, Upper Saddle River, New Jersey (NJ) 07458; and **Manuel Modiano**, a citizen of the United States of America, with a post office address of 11054 E Startender PL, Tucson, Arizona (AZ) 85749-8020, hereinafter generally referred to collectively as "**ASSIGNORS**," have invented certain new and useful invention(s) that are described in the following patent applications ("**Inventions**") naming us, the above ASSIGNORS, as inventors:

| Application Serial No. | Title | Filing Date or 371(c) Date | Patent No. |
|-------------------------------|--|-----------------------------------|-------------------|
| 13/950,316 | Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration | 07/25/2013 | - |
| 13/620,852 | Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration | 09/15/2012 | 8,552,056 |
| 12/873,477 | Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration | 09/01/2010 | 8,273,789 |
| PCT/US2008/055384 | Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration | 02/28/2008 | - |
| 60/911,607 | Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration | 04/13/2007 | - |
| 60/908,459 | Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration | 03/28/2007 | - |
| 12/593,153 | Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration | 02/28/2008 | - |
| 13/785,753 | Taxane Analogs For The Treatment Of Brain Cancer | 03/05/2013 | |
| 12/859,990 | Taxane Analogs For The Treatment Of Brain Cancer | 08/20/2010 | 8,409,574 |
| PCT/US2008/055367 | Taxane Analogs For The Treatment Of Brain Cancer | 02/28/2008 | - |
| 60/894,169 | Taxane Analogs For The Treatment Of Brain | 03/09/2007 | - |

| Application Serial No. | Title | Filing Date or 371(c) Date | Patent No. |
|------------------------|--|----------------------------|------------|
| | Cancer | | |
| 60/892,235 | Taxane Analogs For The Treatment Of Brain Cancer | 02/28/2007 | - |
| 12/529,122 | Taxane Analogs For The Treatment Of Brain Cancer | 02/28/2008 | - |

WHEREAS, TAPESTRY PHARMACEUTICALS, INC., a corporation having a place of business at 80 Seville Chase, Atlanta, Georgia (GA) 30328, United States of America, hereinafter generally referred to as "ASSIGNEE," is desirous of acquiring and/or confirming the acquisition of said Inventions.

NOW, THEREFORE, in consideration of the sum of one dollar and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged and intending to be legally bound hereby, we, the undersigned ASSIGNORS, have assigned and/or by these presents do sell, assign, transfer and convey unto the above-named ASSIGNEE, the whole and entire right, title and interest:

in and to said Inventions as described in the above patent application, for the territory of the United States and its possessions and territories and all foreign countries;

in and to the above patent application and any and all United States and foreign patent applications disclosing said Inventions including, without limitation, applications for patents including provisionals, non-provisionals, divisions, continuations, continuations-in-part, requests for continued examinations, utility models, PCT applications and designs and any other related United States and foreign applications and equivalents thereof ("Applications"), along with the right to claim priority to said Applications under any treaty relating thereto;

in and to all United States and foreign patents, utility models, inventor's certificates and designs and all equivalents thereof which may be granted for said Inventions or Applications, including extensions, renewals, reissues and reexamination certificates thereof ("Patents"); and

in and to all rights to sue for and collect damages resulting from past, present and future infringement of all granted or to be granted Patents;

said Inventions, Applications and Patents to be held and enjoyed by the above-named ASSIGNEE, for ASSIGNEE's own use and benefit, and for ASSIGNEE's legal representatives and assigns to the full end of the term or terms for which said granted or to be granted Patents, as fully and entirely as the same would have been held by the undersigned ASSIGNORS had this assignment and sale not been made; and for the aforesaid consideration ASSIGNORS hereby

covenant, agree and undertake to execute, whenever requested by the above-named ASSIGNEE, all patent applications, assignments, lawful oaths and any other papers which ASSIGNEE may deem necessary or desirable for securing to ASSIGNEE or for maintaining for ASSIGNEE all the Applications and Patents hereby assigned or agreed to be assigned; all without further compensation to the undersigned ASSIGNORS.

It is agreed that ASSIGNORS shall be legally bound, upon request and at the expense of ASSIGNEE or its successors or assigns or a legal representative thereof, to supply all information and evidence of which the undersigned has knowledge or possession, relating to the making and practicing of the Inventions, and to testify in any legal proceeding relating thereto.

Each ASSIGNOR hereby represents and warrants that he has full right, power and authority to assign ASSIGNOR'S entire right, title, and interest in said Patents and Applications, and Inventions disclosed therein, and to consummate the assignment contemplated herein. Each ASSIGNOR also represents and warrants that he has full right, power, and authority to enter into, execute, and deliver this Assignment, the execution and delivery of which have been duly authorized by all necessary action on the part of ASSIGNORS, and no other authorization or proceedings on the part of ASSIGNORS are necessary to authorize this Assignment. This Assignment has been duly executed and delivered and constitutes a valid, binding and enforceable assignment of the entire right, title, and interest in the Patents and Applications, and Inventions disclosed therein.

ASSIGNORS hereby warrant that no assignment, sale, agreement, or encumbrance has been or will be made or entered into which would conflict with this Assignment.

(SIGNATURE PAGE FOLLOWS)

(Date) _____ James D. McChesney
NAME OF FIRST INVENTOR

FIRST INVENTOR'S SIGNATURE

(Date) _____ Gilles Tapolsky
NAME of SECOND INVENTOR

SECOND INVENTOR'S SIGNATURE

(Date) _____ David L. Emerson
NAME OF THIRD INVENTOR

THIRD INVENTOR'S SIGNATURE

(Date) _____ John Marshall
NAME of FOURTH INVENTOR

FOURTH INVENTOR'S SIGNATURE

1/29/15

(Date) _____ Tauseef Ahmed
NAME OF FIFTH INVENTOR

FIFTH INVENTOR'S SIGNATURE

(Date) Allen Cohn
NAME of SIXTH INVENTOR

SIXTH INVENTOR'S SIGNATURE

(Date) Michael Kurman
NAME OF SEVENTH INVENTOR

SEVENTH INVENTOR'S SIGNATURE

(Date) Manuel Modiano
NAME of EIGHTH INVENTOR

EIGHTH INVENTOR'S SIGNATURE

(Date) James D. McChesney,
NAME OF FIRST INVENTOR

FIRST INVENTOR'S SIGNATURE

(Date) Gilles Tapolsky
NAME of SECOND INVENTOR

SECOND INVENTOR'S SIGNATURE

Indemnification Obligation:

Whereas, Tauseef Ahmed is a named inventor on a number of patent applications filed by Tapestry Pharmaceuticals, Inc. ("Tapestry") and

Whereas, Tauseef Ahmed has assigned rights to such inventions to Tapestry pursuant to the attached assignment agreement, which has been executed by Dr. Ahmed.

Now, therefore, in consideration for executing such assignment agreement, Tapestry agrees to indemnify and hold Dr. Ahmed harmless for any liability, damages, or costs and expenses associated with or resulting from Tapestry's or any third party's exploitation or practice of such inventions, whether relating to claims of infringement, personal injury, or otherwise.

(Date)

TAPESTRY PHARMACEUTICALS, INC
Marvin A. Davis, Chief Restructuring Officer